Oliver Sartor, MD

Oliver Sartor, MD, discusses the use of PSMA PET and radioligand therapy in prostate cancer.

Oliver Sartor, MD, discusses ongoing prostate cancer research, highlighting the importance of considering patient quality of life.

Before closing out their discussion, experts review novel targeted agents under investigation in metastatic CRPC.

Experts share insight on the greatest unmet needs in treating patients with metastatic castration-resistant prostate cancer.

Andrew J. Armstrong, MD, MSc, breaks down ongoing prostate cancer clinical trials looking at targeted radioligand therapies.

Oliver Sartor, MD, considers the respective roles of Lu-PSMA-617 and radium-223 as radiotherapy in the setting of mCRPC.

Expert perspectives on where Lu-PSMA-617 therapy may fit into the treatment paradigm for metastatic castration-resistant prostate cancer.

A comprehensive review of the design and results of VISION, which analyzed Lu-PSMA-617 therapy in patients with mCRPC.

Expert Scott Tagawa, MD, MS, FACP, details the role of radium-223 in treating metastatic CRPC and highlights real-world experiences.

Shared insight on the key factors that play into the selection of therapy for patients with metastatic castration-resistant prostate cancer.

A detailed review of the available pharmacologic agents used to treat patients with metastatic castration-resistant prostate cancer.

A brief discussion on how novel imaging strategies are being used to inform the treatment of patients with prostate cancer.

Expert perspectives on phenotypic biomarkers in prostate cancer and their role in comparison to genotypic biomarkers.

Broad discussion on the role of biomarker testing in prostate cancer, particularly how it has helped to inform therapy selection and patient management.

Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer and the potential for combinations with this agent.

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the science behind the results of a study investigating sipuleucel-T (Provenge) for patients with castration-resistant prostate cancer (CRPC).

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the next steps with sipuleucel-T (Provenge) for patients with prostate cancer.

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the remaining questions with sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer.

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the implications of the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

Oliver Sartor, MD, medical director of Tulane Cancer Center, discusses the mechanism of action of radium-223 dichloride (Xofigo) as well as its safety profile for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses key points for community oncologists regarding radium-223 for the treatment of prostate cancer.

Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses sequencing therapies and potential targets in prostate cancer.

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a trial that would study Provenge (sipuleucel-T) in combination with radium-223 as a potential treatment option for patients with prostate cancer.

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the controversies surrounding PSA screening for prostate cancer.

A. Oliver Sartor, MD, Director of the Tulane Cancer Center, discusses the recent progress for the treatment of prostate cancer.

A. Oliver Sartor, MD, Director of the Tulane Cancer Center, describes the mechanism of action of radium-223 for bone metastases from prostate cancer.

Dr. Oliver Sartor, from Tulane Cancer Center, Discusses Prostate-Specific Antigen (PSA) Screening